← back to search

Cornelius J. Clancy

University of Pittsburgh · US
Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include Antifungal resistance and susceptibility, Fungal Infections and Studies, Antibiotic Resistance in Bacteria, and Antibiotics Pharmacokinetics and Efficacy.
h-index
77
citations
27,679
works
392
NIH funding
primary concept
Medicine
email

Recent publications

Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM
The Lancet Infectious Diseases 2025cited by 262position: middledoi
Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients
The Lancet Respiratory Medicine 2024cited by 94position: middledoi
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
Clinical Infectious Diseases 2023cited by 664position: lastdoi
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>)
Clinical Infectious Diseases 2022cited by 483position: lastdoi
Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases
Open Forum Infectious Diseases 2022cited by 47position: middledoi
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant<i>Acinetobacter baumannii</i>, and<i>Stenotrophomonas maltophilia</i>Infections
Clinical Infectious Diseases 2021cited by 505position: lastdoi
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and<i>Pseudomonas aeruginosa</i>with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>)
Clinical Infectious Diseases 2021cited by 391position: lastdoi
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis
Intensive Care Medicine 2021cited by 159position: middledoi
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.
2021cited by 127position: contributordoi
Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance
Transactions of the Royal Society of Tropical Medicine and Hygiene 2021cited by 104position: middledoi
Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic
Journal of Global Antimicrobial Resistance 2021cited by 56position: middledoi
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion
Intensive Care Medicine 2020cited by 442position: middledoi
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>)
Clinical Infectious Diseases 2020cited by 421position: lastdoi
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.
2020cited by 342position: contributordoi
Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19
Open Forum Infectious Diseases 2020cited by 87position: middledoi
Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000–2017
Clinical Infectious Diseases 2020cited by 66position: middledoi
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
Clinical Infectious Diseases 2019cited by 2,757position: middledoi
Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections
Annals of Internal Medicine 2019cited by 112position: middledoi
Pharmacokinetics and Dialytic Clearance of Isavuconazole during <i>In Vitro</i> and <i>In Vivo</i> Continuous Renal Replacement Therapy
Antimicrobial Agents and Chemotherapy 2019cited by 17position: middledoi
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Antimicrobial Agents and Chemotherapy 2018cited by 285position: lastdoi
Efficacy of T2 Magnetic Resonance Assay in Monitoring Candidemia after Initiation of Antifungal Therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) Trial
Journal of Clinical Microbiology 2018cited by 76position: middledoi
How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers
Clinical Infectious Diseases 2018cited by 43position: middledoi
Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms
Journal of Antimicrobial Chemotherapy 2018cited by 17position: middledoi
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Antimicrobial Agents and Chemotherapy 2017cited by 483position: lastdoi
Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel
Clinical Infectious Diseases 2017cited by 168position: firstdoi
Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Clinical Infectious Diseases 2016cited by 1,281position: middledoi
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne <i>bla</i> <sub>KPC-3</sub> Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
Antimicrobial Agents and Chemotherapy 2016cited by 483position: lastdoi
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
Clinical Infectious Diseases 2016cited by 424position: middledoi
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Clinical Infectious Diseases 2015cited by 3,983position: middledoi
T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial
Clinical Infectious Diseases 2015cited by 432position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

M. Hong Nguyen · University of Pittsburgh15 papers (2013–2022)Ryan K. Shields · University of Pittsburgh8 papers (2014–2020)Peter G. Pappas · University of Alabama at Birmingham8 papers (2015–2022)Pranita D. Tamma · Johns Hopkins University5 papers (2020–2023)Amy J. Mathers · University of Virginia Health System5 papers (2020–2023)Luis Ostrosky‐Zeichner · Texas Medical Center5 papers (2015–2022)David van Duin · University of North Carolina at Chapel Hill5 papers (2020–2023)Samuel L Aitken · University of Michigan–Ann Arbor5 papers (2020–2023)José A. Vázquez · Augusta University5 papers (2014–2017)Robert A. Bonomo · Louis Stokes Cleveland VA Medical Center5 papers (2020–2023)Ellen G. Press · University of Pittsburgh4 papers (2016–2018)Barry N. Kreiswirth · Center for Discovery4 papers (2016–2018)Liang Chen · South China Agricultural University4 papers (2016–2018)Eleftherios Mylonakis · Houston Methodist4 papers (2015–2022)Brian A. Potoski · University of Pittsburgh3 papers (2014–2017)Dimitrios P. Kontoyiannis · The University of Texas MD Anderson Cancer Center3 papers (2015–2022)Annette C. Reboli · Twitter (United States)3 papers (2015–2017)Carol A. Kauffman · University of Arizona3 papers (2015–2022)Yohei Doi · University of Pittsburgh3 papers (2016–2017)Thomas F. Patterson · University of Illinois Chicago3 papers (2013–2022)